Freeline Revenue and Competitors

Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver. Our vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-off curative treatment. Freeline has developed a next generation AAV based gene therapy platform to provide treatments for a wide range of diseases like haemophilia B, Fabry and Gaucher Disease which have previously been underserved and incurable. We are headquartered in the UK and we also have operations in Germany and the US. Founded in 2015, Freeline has since grown to be a leading clinical stage gene therapy company. Our gene therapy builds upon the pioneering work by the Freeline CSO, Professor Amit Nathwani, Professor of Haematology at UCL. The ambitious Freeline vision is to create better lives for people suffering from chronic, debilitating disease. At our heart is innovation combined with an entrepreneurial spirit, and a shared purpose in making a life-changing impact, through the potential of our research and product pipeline. We have ambitious plans to grow rapidly in Europe, and in other regions, as we develop our life-changing therapies. If you are interested in joining our team and help make our life-changing vision a reality, go to our website for further information. Please read our Community Guidelines before engaging with us on LinkedIn: https://www.freeline.life/about-us/freeline-social-media-community-engagement-guidelines/